- 1 Clinical Question
- 2 Bottom Line
- 3 Major Points
- 4 Guidelines
- 5 Design
- 6 Population
- 7 Interventions
- 8 Outcomes
- 9 Criticisms
- 10 Funding
- 11 Further Reading
In patients with acute hypoxemic respiratory failure without hypercapnia, does high-flow oxygen therapy decrease intubation and mortality rates compared to noninvasive ventilation or standard oxygen therapy?
ICU and 90-day mortality were significantly reduced in patients with acute hypoxemic respiratory failure without hypercapnia given high-flow oxygen therapy compared to noninvasive ventilation or standard oxygen therapy.
There are multiple methods of delivering oxygen that aim to minimize intubation rate and mortality, such as nasal cannula, non-rebreather mask, and noninvasive positive-pressure ventilation (NIPPV) such as BiPAP and CPAP. There is high quality data that NIPPV reduces intubation rate and mortality in COPD exacerbations and cardiogenic pulmonary edema, however its benefits in other forms of acute hypoxemic respiratory failure have yet to be clearly demonstrated.
The FLORALI trial (2015) demonstrated the effectiveness of a new method of oxygen delivery called high-flow nasal cannula in a well-defined subset of patients in acute respiratory failure: those with hypoxemia and without hypercapnia. In this randomized controlled trial, high-flow oxygen therapy had a significant improvement in 90-day mortality compared to either noninvasive ventilation or standard oxygen therapy (12% vs. 28% vs. 23%). While there was no significant reduction in intubation rate overall, patients with more severe hypoxemia, PaO2:FiO2 ≤ 200 mmHg, did experience a significant reduction in intubation rates with high-flow oxygen therapy, which may have driven this mortality benefit.
- Canadian Critical Care Trials Group, Noninvasive Ventilation Guidelines, 2011
- We make no recommendation about the use of NIPPV in patients who have acute lung injury, because of a lack of RCTs.
- We make no recommendation about the use of NIPPV in patients who have severe community-acquired pneumonia and no prior history of COPD
- We recommend the use of NIPPV in patients who have a severe exacerbation of COPD (Grade 1A).
- We recommend the use of NIPPV or CPAP in patients who have cardiogenic pulmonary edema and respiratory failure in the absence of shock or ACS requiring urgent revascularization (Grade 1A).
- Multicenter, open label, randomized, controlled trial
- High-flow oxygen therapy (n=106)
- Standard oxygen therapy (n=94)
- Noninvasive ventilation (n=110)
- Setting: 23 ICU centers in France and Belgium
- Enrollment: February 2011 to April 2013
- Complete follow-up at 90 days
- Analysis: Intention-to-treat
- Primary outcome: Proportion of patients intubated at day 28
- RR ≥ 25, AND
- PaO2:FiO2 ≤ 300 mmHg, AND (while patient breathing O2 ≥ 10L/min)
- PaCO2 ≤ 45 mmHg, AND
- No clinical history of chronic respiratory failure
- Cardiogenic pulmonary edema
- Severe neutropenia
- Hemodynamic instability
- Contraindication to NIPPV (e.g. low GCS)
- Urgent need for intubation
“Similar in all three groups”
- Age: 60
- 64% caused by community-acquired pneumonia
- 77% PaO2:FiO2 ≤ 200 mmHg
- Mean FiO2: 0.65
- SAPS II: 25
- Randomized to one of three groups:
- High-flow oxygen therapy: Continuous oxygen through heated humidifier and large binasal prongs, with 50L/min flow at 1.0 FiO2, adjusted to goal: SpO2 ≥ 92%
- Standard oxygen therapy: Continuous nonrebreather face mask, ≥ 10 L/min, Goal: SpO2 ≥ 92%
- Noninvasive ventilation: Face mask connected to ventilator with pressure support adjusted to 7-10 ml/kg (PBW) and PEEP 2-10 cm H2O, with adjustment of PEEP/FiO2 to maintain SpO2 ≥ 92%
- Minimum of 2 calendar days on therapy before switch to standard oxygen therapy allowed
- Between noninvasive ventilation sessions, patients received high-flow oxygen
Comparisons are high-flow vs. standard oxygen vs. noninvasive ventilation.
- Proportion of patients intubated at day 28
- 38% vs. 47% vs. 50% (P=0.18)
- Standard oxygen vs. High-flow: OR 1.45 (0.83–2.55)
- Noninvasive ventilation vs. High-flow: OR 1.65 (0.96–2.84)
- All-cause mortality in the ICU
- 11% vs. 19% vs. 25% (P=0.047)
- Standard oxygen vs. High-flow: OR 1.85 (0.84–4.09)
- Noninvasive ventilation vs. High-flow: OR 2.55 (1.21–5.35)
- All-cause mortality at 90 days
- 12% vs. 23% vs. 28% (P=0.02)
- Standard oxygen vs. High-flow: OR 2.01 (1.01–3.99)
- Noninvasive ventilation vs. High-flow: OR 2.50 (1.31–4.78)
- Number of ventilator-free days at day 28
- 24 vs. 22 vs. 19 days (P=0.02)
- Patients with PaO2
- FiO2 ≤ 200 mmHg:
- Intubation rate: 35% vs. 53% vs. 58% (P=0.01)
- Number of ventilator-free days: 24 vs. 22 vs. 18 days (P<0.001)
- Cause of death
- Refractory shock: 46% vs 55% vs 58% (P=0.04)
- Marked improvement – 22% vs. 7% vs. 14%
- Slight improvement– 54% vs. 34% vs. 44%
- No significant difference between groups
- Number of cardiac arrests occurring before intubation: 2 vs. 1 vs. 0
- Since the majority (>80%) of these patients had pneumonia, it may be inaccurate to generalize these results to sepsis and other causes of acute hypoxemic respiratory failure without hypercapnia.
- This study was underpowered to detect or reject more subtle differences (<20%) in intubation rates.
- Patients in the noninvasive ventilation group received high-flow oxygen between treatments, which may not accurately represent the realistic comparison. Further, the two therapies may have an antagonistic relationship when used in combination.
Funded by the Programme Hospitalier de Recherche Clinique Interrégional 2010 of the French Ministry of Health. Equipment donated by Fisher and Paykel Healthcare who played no other role in the study.
- Noninvasive Ventilation for Acute Exacerbations of Chronic Obstructive Pulmonary Disease. NEJM. 1995.
- Meta-analysis: Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema. Annals. 2010.
- Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting. CMAJ. 2011.